
## Daniel Baumgart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8208531/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Crohn's disease. Lancet, The, 2012, 380, 1590-1605.	6.3	1,722
2	Inflammatory bowel disease: cause and immunobiology. Lancet, The, 2007, 369, 1627-1640.	6.3	1,656
3	Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, The, 2007, 369, 1641-1657.	6.3	1,593
4	An overview of clinical decision support systems: benefits, risks, and strategies for success. Npj Digital Medicine, 2020, 3, 17.	5.7	992
5	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. Journal of Crohn's and Colitis, 2019, 13, 144-164K.	0.6	958
6	Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet, The, 2016, 388, 1281-1290.	6.3	771
7	Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clinical Gastroenterology and Hepatology, 2020, 18, 1663-1672.	2.4	437
8	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet, The, 2014, 384, 309-318.	6.3	421
9	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology, 2018, 154, 1334-1342.e4.	0.6	331
10	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. Journal of Crohn's and Colitis, 2019, 13, 273-284.	0.6	250
11	Intestinal barrier function. Current Opinion in Clinical Nutrition and Metabolic Care, 2002, 5, 685-694.	1.3	204
12	Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology, 2012, 20, 1-18.	1.9	172
13	Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study. Alimentary Pharmacology and Therapeutics, 2016, 43, 1090-1102.	1.9	155
14	Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. New England Journal of Medicine, 2021, 385, 1302-1315.	13.9	137
15	Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology, 2016, 150, 477-487.e9.	0.6	133
16	Personal digital assistants in health care: experienced clinicians in the palm of your hand?. Lancet, The, 2005, 366, 1210-1222.	6.3	127
17	US-based Real-time Elastography for the Detection of Fibrotic Gut Tissue in Patients with Stricturing Crohn Disease. Radiology, 2015, 275, 889-899.	3.6	111
18	Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut, 2005, 54, 228-236.	6.1	108

DANIEL BAUMGART

#	Article	IF	CITATIONS
19	Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. Frontiers in Pharmacology, 2019, 10, 279.	1.6	89
20	Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, antiâ€TNF or conventional therapy: results of the European CONCEIVE study. Alimentary Pharmacology and Therapeutics, 2020, 51, 129-138.	1.9	87
21	Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clinical and Experimental Immunology, 2009, 157, 423-436.	1.1	77
22	Colon cleansing efficacy and safety with 1 L NER1006 versus sodium picosulfate with magnesium citrate: a randomized phase 3 trial. Endoscopy, 2019, 51, 73-84.	1.0	65
23	The Diagnosis and Treatment of Crohn's Disease and Ulcerative Colitis. Deutsches Ärzteblatt International, 2009, 106, 123-33.	0.6	64
24	Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitis. Clinical and Experimental Immunology, 2011, 166, 46-54.	1.1	62
25	Smartphones in Clinical Practice, Medical Education, and Research. Archives of Internal Medicine, 2011, 171, 1294.	4.3	62
26	Effectiveness and Safety of Vedolizumab in Anti-TNF-NaÃ⁻ve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study. Inflammatory Bowel Diseases, 2018, 24, 2442-2451.	0.9	56
27	Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients. Inflammatory Bowel Diseases, 2011, 17, 2512-2520.	0.9	53
28	Digital advantage in the COVID-19 response: perspective from Canada's largest integrated digitalized healthcare system. Npj Digital Medicine, 2020, 3, 114.	5.7	52
29	Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitisâ€. Inflammatory Bowel Diseases, 2010, 16, 620-629.	0.9	46
30	Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. The Cochrane Library, 2008, , CD007216.	1.5	42
31	Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver. Gastrointestinal Endoscopy, 2005, 61, 473-475.	0.5	41
32	Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images. Scientific Reports, 2022, 12, 2748.	1.6	38
33	Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. Journal of Crohn's and Colitis, 2016, 10, 812-820.	0.6	35
34	Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: longâ€ŧerm extension data from a Phase 3 study. Alimentary Pharmacology and Therapeutics, 2016, 44, 259-270.	1.9	34
35	The c.1-260C>T Promoter Variant of CD14 but Not the c.896A>G (p.D299G) Variant of Toll-Like Receptor 4 (TLR4) Genes Is Associated with Inflammatory Bowel Disease. Digestion, 2007, 76, 196-202.	1.2	33
36	Tablet computer enhanced training improves internal medicine exam performance. PLoS ONE, 2017, 12, e0172827.	1.1	31

DANIEL BAUMGART

#	Article	IF	CITATIONS
37	Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme. Journal of Crohn's and Colitis, 2021, 15, 914-929.	0.6	29
38	Transient Cytokine-Induced Liver Injury Following Administration of the Humanized Anti-CD3 Antibody Visilizumab (HuM291) in Crohn's Disease. American Journal of Gastroenterology, 2009, 104, 868-876.	0.2	26
39	Autoimmunity in Crohn's Disease—A Putative Stratification Factor of the Clinical Phenotype. Advances in Clinical Chemistry, 2016, 77, 77-101.	1.8	24
40	Vedolizumab safety in pregnancy and newborn outcomes. Gut, 2017, 66, 1866-1867.	6.1	24
41	Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study. Journal of Crohn's and Colitis, 2018, 12, 188-196.	0.6	24
42	Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease. Gastroenterology, 2018, 154, 752-754.e1.	0.6	24
43	Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues. Journal of Crohn's and Colitis, 2016, 10, 31-37.	0.6	20
44	Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 386-388.	1.9	20
45	Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre populationâ€based cohort study. Alimentary Pharmacology and Therapeutics, 2021, 54, 1320-1329.	1.9	19
46	Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany – a real-world evidence analysis. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 93-103.	0.7	16
47	What's new in inflammatory bowel disease in 2008?. World Journal of Gastroenterology, 2008, 14, 329.	1.4	16
48	Darvadstrocel for the treatment of perianal fistulas in Crohn's disease. Expert Review of Gastroenterology and Hepatology, 2020, 14, 405-410.	1.4	15
49	Current Biological Therapies for Inflammatory Bowel Disease. Current Pharmaceutical Design, 2004, 10, 4127-4147.	0.9	15
50	Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype. Frontiers in Immunology, 2018, 9, 1959.	2.2	13
51	Improved high-quality colon cleansing with 1L NER1006 versus 2L polyethylene glycol + ascorbate or oral sulfate solution. Digestive and Liver Disease, 2019, 51, 1671-1677.	0.4	12
52	Perspectives of the International Society for Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi). Cytotherapy, 2019, 21, 824-839.	0.3	12
53	Perceived distress, personality characteristics, coping strategies and psychosocial impairments in a national German multicenter cohort of patients with Crohn's disease and ulcerative colitis. Zeitschrift Fur Gastroenterologie, 2019, 57, 473-483.	0.2	11
54	The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds. PLoS ONE, 2016, 11, e0147364.	1.1	11

DANIEL BAUMGART

#	Article	IF	CITATIONS
55	Virchow's node. Lancet, The, 2007, 370, 1568.	6.3	9
56	Endoscopic Surveillance in Crohn's Disease and Ulcerative Colitis: Who Needs What and When?. Digestive Diseases, 2011, 29, 32-35.	0.8	8
57	Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab. Drug Design, Development and Therapy, 2015, 9, 147.	2.0	7
58	Probe-Based Confocal Laser Microscopy Identifies Criteria Predictive of Active Celiac Sprue. Digestive Diseases and Sciences, 2012, 57, 451-457.	1.1	5
59	P603 INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn's disease and complex perianal fistulas. Journal of Crohn's and Colitis, 2022, 16, i536-i537.	0.6	5
60	Tablet computer-based multimedia enhanced medical training improves performance in gastroenterology and endoscopy board style exam compared with traditional medical education. Gut, 2016, 65, 535-536.	6.1	4
61	Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis. Evidence-Based Medicine, 2011, 16, 71-72.	0.6	3
62	How many lives does an ulcerative colitis patient have?. Lancet, The, 2010, 376, 928.	6.3	2
63	CB-01-05-MMX, a novel oral controlled-release low molecular weight heparin for the potential treatment of ulcerative colitis. Current Opinion in Investigational Drugs, 2010, 11, 571-6.	2.3	2
64	Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial. Digestive Diseases and Sciences, 2020, 66, 3985-3992.	1.1	1
65	A80 ADHERENCE TO GUIDELINES AND BEST PRACTICES FOR IBD FLARE MANAGEMENT AND CORTICOSTEROID ADMINISTRATION: A RETROSPECTIVE CHART REVIEW. Journal of the Canadian Association of Gastroenterology, 2019, 2, 160-162.	0.1	0
66	A110 CLINICAL DECISION SUPPORT SYSTEM FOR IBD FLARE MANAGEMENT AND CORTICOSTEROID ADMINISTRATION: PRELIMINARY RESULTS FROM AN INTERRUPED TIME SERIES. Journal of the Canadian Association of Gastroenterology, 2019, 2, 219-220.	0.1	0
67	Photo quiz. Obesity and daytime sleepiness. Prader-Willi syndrome. American Family Physician, 2003, 68, 151-2.	0.1	0